HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Review Of Dietary Ingredients For Pharmacy Compounding Could Open Door To Change DSHEA

This article was originally published in The Rose Sheet

Executive Summary

FDA could look for Congress to amend DSHEA as it creates a “deep” administrative record on dietary ingredients placed on a list of substances no longer allowed for use by compounding pharmacies, says integrative medicine attorney Alan Dumoff. Pharmacy organizations are writing a citizen petition to ward off what they fear will be an excuse to step-up regulation of supplement manufacturing and marketing.

You may also be interested in...



Clinical Trials For Supplement Claims Not An FTC Rule, But A Standard

FTC Bureau of Consumer Protection official Richard Cleland takes on the hot-button issue by explaining that a supplement health or structure/function claim doesn't need support from research with the size and scope of studies looking at the safety and efficacy of a drug ingredient proposed for a certain indication. Supplement ad claims, though, still need competent and reliable scientific evidence as support.

US FDA Officials Exhort Compounding Pharmacies To Improve Drug Quality

Will lessons from New England Compounding Center ever be learned? Top FDA officials say that compounding pharmacies need up their game and do a better job of producing quality sterile drugs as way too many facilities are failing GMP inspections and producing drugs that are sickening – and even killing – patients. Officials say forthcoming final guidance and final USP standard should turn this situation around.

Hatch Question, Gottlieb Response Speak Volumes About DSHEA Reliance

Gottlieb is not the first FDA commissioner nominee to profess support for its regulatory framework established by DSHEA, but the focus of Hatch's question serves stronger notice than similar questions asked of previous candidates that the agency authority to enforce in the space does need adjustment.

Topics

UsernamePublicRestriction

Register

RS122497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel